FFA
ABMD

Freedman Financial Associates’s Abiomed Inc ABMD Stock Holding History

Freedman Financial Associates’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$32K – 482
2020
Q4 		$32K Buy
+100
New +$27.7K 0.03% 241

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Freedman Financial Associates's ABMD Position: Q1 2021 in Review

Freedman Financial Associates sold out of Abiomed Inc (ABMD) in Q1 2021, closing a stake of 100 shares — an estimated $32K sold.

Freedman Financial Associates first reported a position in ABMD in Q4 2020 and held it in 1 quarter. The position peaked at $32K in Q4 2020. 487 funds tracked by Wall St. Rank hold ABMD as of Q1 2021.

  • Freedman Financial Associates reported no remaining Abiomed Inc position as of Q1 2021 after selling out during the quarter.
  • Freedman Financial Associates sold 100 Abiomed Inc shares in Q1 2021, an estimated $32K.
  • Freedman Financial Associates first reported a position in Abiomed Inc in Q4 2020 and held it in 1 quarter.
  • Freedman Financial Associates's Abiomed Inc position peaked at $32K in Q4 2020.
  • 487 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2021.

Based on Freedman Financial Associates's 13F filing for Q1 2021, filed 17 May 2021.